The role of proteomics in the modern diagnosis of cervical cancer

Abstract

Cervical cancer is a leading global health problem and the second most common form of cancer in women living in developing countries. Despite the available methods of diagnosis and treatment, cervical cancer is still the cause of a large number of deaths among vulnerable groups of the female population, which makes further research relevant. The aim of this study was to summarize new technological developments and scientific information about proteomics, which will allow for deepening the understanding of the pathogenesis of cervical cancer and developing new methods of diagnosis and treatment of this pathology. Recent achievements in the field of analytical research methods and bioinformatics provide a wide range of alternatives in the field of proteomic research. To date, proteomic analysis can be performed on almost any biological sample (tumor tissue, blood, urine, saliva, vaginal secretions). Each type of biological sample represents a potential source of diagnostic and prognostic biomarkers, as well as potential targets for therapy. The main limitation of proteomic studies aimed at finding potential biomarkers of the disease is the high variability of the results depending on the specific laboratory. There is variability in concentrations and even in the type of biomarker identified, even though research teams are working with the same samples.

Keywords

cervical cancer / proteomics / biomarkers / proteins

References

[1] Zhukova AB. Squamous intraepithelial lesions of the cervix: a modern view of etiology, pathogenesis, and diagnosis. Journal of obstetrics and women’s diseases. 2019;68(6):87–98. (In Russ.). DOI: 10.17816/JOWD68687-98

[2] Жукова А.Б. Плоскоклеточные интраэпителиальные поражения шейки матки: современный взгляд на этиологию, патогенез, диагностику // Журнал акушерства и женских болезней. 2019. Т. 68. № 6. C. 87–98. DOI: 10.17816/JOWD68687-98

[3] Pestrikova TY, Ismaylova AF, Kiselev SN. Cervical cancer: monitoring of the main indicators characterizing this pathology in Khabarovsk Krai (2009–2019). Gynecology. 2021;23(2):155–160. (In Russ.). DOI: 10.26442/20795696.2021.2.200775

[4] Пестрикова Т.Ю., Исмайлова А.Ф., Киселев С.Н. Рак шейки матки: мониторирование основных показателей, характеризующих данную патологию, в Хабаровском крае (2009–2019 гг.) // Гинекология. 2021. Т. 23. № 2. C. 155–160. DOI: 10.26442/20795696.2021.2.200775

[5] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. DOI: 10.3322/caac.21660

[6] Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J. Clin. 2021. Vol. 71. No. 3. P. 209–249. DOI: 10.3322/caac.21660

[7] Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med. 2018;7(10):5217–5236. DOI: 10.1002/cam4.1501

[8] Hu Z., Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications // Cancer Med. 2018. Vol. 7 No. 10. P. 5217–5236. DOI: 10.1002/cam4.1501

[9] Wang D, Eraslan B, Wieland T, et al. A deep proteome and transcriptome abundance atlas of 29 healthy human tissues. Mol Syst Biol. 2019;15(2):e8503. DOI: 10.15252/msb.20188503

[10] Wang D., Eraslan B., Wieland T. et al. A deep proteome and transcriptome abundance atlas of 29 healthy human tissues // Mol. Syst. Biol. 2019. Vol. 15. No. 2. P. e8503. DOI: 10.15252/msb.20188503

[11] Rao VS, Srinivas K, Sujini GN, Kumar GN. Protein-protein interaction detection: methods and analysis. Int J Proteomics. 2014;2014:147648. DOI: 10.1155/2014/147648

[12] Rao V.S., Srinivas K., Sujini G.N., Kumar G.N. Protein-protein interaction detection: methods and analysis // Int. J. Proteomics. 2014. Vol. 2014. P. 147648. DOI: 10.1155/2014/147648

[13] Droit A, Poirier GG, Hunter JM. Experimental and bioinformatic approaches for interrogating protein-protein interactions to determine protein function. J Mol Endocrinol. 2005;34(2):263–280. DOI: 10.1677/jme.1.01693

[14] Droit A., Poirier G.G., Hunter J.M. Experimental and bioinformatic approaches for interrogating protein-protein interactions to determine protein function // J. Mol. Endocrinol. 2005. Vol. 34. No. 2. P. 263–280. DOI: 10.1677/jme.1.01693

[15] Pascovici D, Wu JX, McKay MJ, et al. Clinically relevant post-translational modification analyses-maturing workflows and bioinformatics tools. Int J Mol Sci. 2018;20(1):16. DOI: 10.3390/ijms20010016

[16] Pascovici D., Wu J.X., McKay M.J. et al. Clinically relevant post-translational modification analyses-maturing workflows and bioinformatics tools // Int. J. Mol. Sci. 2018. Vol. 20. No. 1. P. 16. DOI: 10.3390/ijms20010016

[17] O’Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 1975;250(10):4007–4021.

[18] O’Farrell P.H. High resolution two-dimensional electrophoresis of proteins // J. Biol. Chem. 1975. Vol. 250. No. 10. P. 4007–4021.

[19] Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226(1):497–509.

[20] Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues // J. Biol. Chem. 1957. Vol. 226. No. 1. P. 497–509.

[21] Chen C, Hou J, Tanner JJ, Cheng J. Bioinformatics methods for mass spectrometry-based proteomics data analysis. Int J Mol Sci. 2020;21(8):2873. DOI: 10.3390/ijms21082873

[22] Chen C., Hou J., Tanner J.J., Cheng J. Bioinformatics methods for mass spectrometry-based proteomics data analysis // Int. J. Mol. Sci. 2020. Vol. 21. No. 8. P. 2873. DOI: 10.3390/ijms21082873

[23] Perkins RC. Making the case for functional proteomics. Methods Mol Biol. 2019;1871:1–40. DOI: 10.1007/978-1-4939-8814-3_1

[24] Perkins R.C. Making the case for functional proteomics // Methods Mol. Biol. 2019. Vol. 1871. P. 1–40. DOI: 10.1007/978-1-4939-8814-3_1

[25] Shin J, Lee W, Lee W. Structural proteomics by NMR spectroscopy. Expert Rev Proteomics. 2008;5(4):589–601. DOI: 10.1586/14789450.5.4.589

[26] Shin J., Lee W., Lee W. Structural proteomics by NMR spectroscopy // Expert Rev. Proteomics. 2008. Vol. 5. No. 4. P. 589–601. DOI: 10.1586/14789450.5.4.589

[27] Boersema PJ, Kahraman A, Picotti P. Proteomics beyond large-scale protein expression analysis. Curr Opin Biotechnol. 2015;34:162–170. DOI: 10.1016/j.copbio.2015.01.005

[28] Boersema P.J., Kahraman A., Picotti P. Proteomics beyond large-scale protein expression analysis // Curr. Opin. Biotechnol. 2015. Vol. 34. P. 162–170. DOI: 10.1016/j.copbio.2015.01.005

[29] Banach P, Suchy W, Dereziński P, et al. Mass spectrometry as a tool for biomarkers searching in gynecological oncology. Biomed Pharmacother. 2017;92:836–842. DOI: 10.1016/j.biopha.2017.05.146

[30] Banach P., Suchy W., Dereziński P. et al. Mass spectrometry as a tool for biomarkers searching in gynecological oncology // Biomed. Pharmacother. 2017. Vol. 92. P. 836–842. DOI: 10.1016/j.biopha.2017.05.146

[31] Al-Wajeeh AS, Salhimi SM, Al-Mansoub MA, et al. Comparative proteomic analysis of different stages of breast cancer tissues using ultra high performance liquid chromatography tandem mass spectrometer. PLoS One. 2020;15(1):e0227404. DOI: 10.1371/journal.pone.0227404

[32] Al-Wajeeh A.S., Salhimi S.M., Al-Mansoub M.A. et al. Comparative proteomic analysis of different stages of breast cancer tissues using ultra high performance liquid chromatography tandem mass spectrometer // PLoS One. 2020. Vol. 15. No. 1. P. e0227404. DOI: 10.1371/journal.pone.0227404

[33] Aslam B, Basit M, Nisar MA, et al. Proteomics: Technologies and their applications. J Chromatogr Sci. 2017;55(2):182–196. DOI: 10.1093/chromsci/bmw167

[34] Aslam B., Basit M., Nisar M.A. et al. Proteomics: Technologies and their applications // J. Chromatogr. Sci. 2017. Vol. 55. No. 2. P. 182–196. DOI: 10.1093/chromsci/bmw167

[35] Boylan KLM, Afiuni-Zadeh S, Geller MA, et al. Evaluation of the potential of Pap test fluid and cervical swabs to serve as clinical diagnostic biospecimens for the detection of ovarian cancer by mass spectrometry-based proteomics. Clin Proteomics. 2021;18(1):4. DOI: 10.1186/s12014-020-09309-3

[36] Boylan K.L.M., Afiuni-Zadeh S., Geller M.A. et al. Evaluation of the potential of Pap test fluid and cervical swabs to serve as clinical diagnostic biospecimens for the detection of ovarian cancer by mass spectrometry-based proteomics // Clin. Proteomics. 2021. Vol. 18. No. 1. P. 4. DOI: 10.1186/s12014-020-09309-3

[37] Chen G, Chen J, Liu H, et al. Comprehensive identification and characterization of human secretome based on integrative proteomic and transcriptomic data. Front Cell Dev Biol. 2019;7:299. DOI: 10.3389/fcell.2019.00299

[38] Chen G., Chen J., Liu H. et al. Comprehensive identification and characterization of human secretome based on integrative proteomic and transcriptomic data // Front. Cell Dev. Biol. 2019. Vol. 7. P. 299. DOI: 10.3389/fcell.2019.00299

[39] Montaner J, Ramiro L, Simats A, et al. Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke. Nat Rev Neurol. 2020;16(5):247–264. DOI: 10.1038/s41582-020-0350-6

[40] Montaner J., Ramiro L., Simats A. et al. Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke // Nat. Rev. Neurol. 2020. Vol. 16. No. 5. P. 247–264. DOI: 10.1038/s41582-020-0350-6

[41] Huang Z, Ma L, Huang C, et al. Proteomic profiling of human plasma for cancer biomarker discovery. Proteomics. 2017;17(6). DOI: 10.1002/pmic.201600240

[42] Huang Z., Ma L., Huang C. et al. Proteomic profiling of human plasma for cancer biomarker discovery // Proteomics. 2017. Vol. 17. No. 6. DOI: 10.1002/pmic.201600240

[43] Ren AH, Fiala CA, Diamandis EP, Kulasingam V. Pitfalls in cancer biomarker discovery and validation with emphasis on circulating tumor DNA. Cancer Epidemiol Biomarkers Prev. 2020;29(12):2568–2574. DOI: 10.1158/1055-9965.EPI-20-0074

[44] Ren A.H., Fiala C.A., Diamandis E.P., Kulasingam V. Pitfalls in cancer biomarker discovery and validation with emphasis on circulating tumor DNA // Cancer Epidemiol. Biomarkers Prev. 2020. Vol. 29. No. 12. P. 2568–2574. DOI: 10.1158/1055-9965.EPI-20-0074

[45] Sobsey CA, Ibrahim S, Richard VR, et al. Targeted and untargeted proteomics approaches in biomarker development. Proteomics. 2020;20(9):e1900029. DOI: 10.1002/pmic.201900029

[46] Sobsey C.A., Ibrahim S., Richard V.R. et al. Targeted and untargeted proteomics approaches in biomarker development // Proteomics. 2020. Vol. 20. No. 9. P. e1900029. DOI: 10.1002/pmic.201900029

[47] Higareda-Almaraz JC, Enríquez-Gasca Mdel R, Hernández-Ortiz M, et al. Proteomic patterns of cervical cancer cell lines, a network perspective. BMC Syst Biol. 2011;5:96. DOI: 10.1186/1752-0509-5-96

[48] Higareda-Almaraz J.C., Enríquez-Gasca Mdel R., Hernández-Ortiz M. et al. Proteomic patterns of cervical cancer cell lines, a network perspective // BMC Syst. Biol. 2011. Vol. 5. P. 96. DOI: 10.1186/1752-0509-5-96

[49] Pappa KI, Christou P, Xholi A, et al. Membrane proteomics of cervical cancer cell lines reveal insights on the process of cervical carcinogenesis. Int J Oncol. 2018;53(5):2111–2122. DOI: 10.3892/ijo.2018.4518

[50] Pappa K.I., Christou P., Xholi A. et al. Membrane proteomics of cervical cancer cell lines reveal insights on the process of cervical carcinogenesis // Int. J. Oncol. 2018. Vol. 53. No. 5. P. 2111–2122. DOI: 10.3892/ijo.2018.4518

[51] Xia C, Yang F, He Z, Cai Y. iTRAQ-based quantitative proteomic analysis of the inhibition of cervical cancer cell invasion and migration by metformin. Biomed Pharmacother. 2020;123:109762. DOI: 10.1016/j.biopha.2019.109762

[52] Xia C., Yang F., He Z., Cai Y. iTRAQ-based quantitative proteomic analysis of the inhibition of cervical cancer cell invasion and migration by metformin // Biomed. Pharmacother. 2020. Vol. 123. P. 109762. DOI: 10.1016/j.biopha.2019.109762

[53] Muñoz N, Bosch FX, de Sanjosé S, et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–527. DOI: 10.1056/NEJMoa021641

[54] Muñoz N., Bosch F.X., de Sanjosé S. et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer // N. Engl. J. Med. 2003. Vol. 348. No. 6. P. 518–527. DOI: 10.1056/NEJMoa021641

[55] Yang J, Chen L, Kong X, et al. Analysis of tumor suppressor genes based on gene ontology and the KEGG pathway. PLoS One. 2014;9(9):e107202. DOI: 10.1371/journal.pone.0107202

[56] Yang J., Chen L., Kong X. et al. Analysis of tumor suppressor genes based on gene ontology and the KEGG pathway // PLoS One. 2014. Vol. 9. No. 9. P. e107202. DOI: 10.1371/journal.pone.0107202

[57] Su PH, Lin YW, Huang RL, et al. Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer. Oncogene. 2013;32(1):15–26. DOI: 10.1038/onc.2012.29

[58] Su P.H., Lin Y.W., Huang R.L. et al. Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer // Oncogene. 2013. Vol. 32. No. 1. P. 15–26. DOI: 10.1038/onc.2012.29

[59] Ma Z, Chen J, Luan T, et al. Proteomic analysis of human cervical adenocarcinoma mucus to identify potential protein biomarkers. PeerJ. 2020;8:e9527. DOI: 10.7717/peerj.9527

[60] Ma Z., Chen J., Luan T. et al. Proteomic analysis of human cervical adenocarcinoma mucus to identify potential protein biomarkers // Peer. J. 2020. Vol. 8. P. e9527. DOI: 10.7717/peerj.9527

[61] Bae SM, Min HJ, Ding GH, et al. Protein expression profile using two-dimensional gel analysis in squamous cervical cancer patients. Cancer Res Treat. 2006;38(2):99–107. DOI: 10.4143/crt.2006.38.2.99

[62] Bae S.M., Min H.J., Ding G.H. et al. Protein expression profile using two-dimensional gel analysis in squamous cervical cancer patients // Cancer Res. Treat. 2006. Vol. 38. No. 2. P. 99–107. DOI: 10.4143/crt.2006.38.2.99

[63] Gu Y, Wu SL, Meyer JL, et al. Proteomic analysis of high-grade dysplastic cervical cells obtained from ThinPrep slides using laser capture microdissection and mass spectrometry. J Proteome Res. 2007;6(11):4256–4268. DOI: 10.1021/pr070319j

[64] Gu Y., Wu S.L., Meyer J.L. et al. Proteomic analysis of high-grade dysplastic cervical cells obtained from ThinPrep slides using laser capture microdissection and mass spectrometry // J. Proteome Res. 2007. Vol. 6. No. 11. P. 4256–4268. DOI: 10.1021/pr070319j

[65] Zhu X, Lv J, Yu L, et al. Proteomic identification of differentially-expressed proteins in squamous cervical cancer. Gynecol Oncol. 2009;112(1):248–256. DOI: 10.1016/j.ygyno.2008.09.045

[66] Zhu X., Lv J., Yu L. et al. Proteomic identification of differentially-expressed proteins in squamous cervical cancer // Gynecol. Oncol. 2009. Vol. 112. No. 1. P. 248–256. DOI: 10.1016/j.ygyno.2008.09.045

[67] Zhao Q, He Y, Wang XL, et al. Differentially expressed proteins among normal cervix, cervical intraepithelial neoplasia and cervical squamous cell carcinoma. Clin Transl Oncol. 2015;17(8):620–631. DOI: 10.1007/s12094-015-1287-x

[68] Zhao Q., He Y., Wang X.L. et al. Differentially expressed proteins among normal cervix, cervical intraepithelial neoplasia and cervical squamous cell carcinoma // Clin. Transl. Oncol. 2015. Vol. 17. No. 8. P. 620–631. DOI: 10.1007/s12094-015-1287-x

[69] Serafín-Higuera I, Garibay-Cerdenares OL, Illades-Aguiar B, et al. Differential proteins among normal cervix cells and cervical cancer cells with HPV-16 infection, through mass spectrometry-based Proteomics (2D-DIGE) in women from Southern México. Proteome Sci. 2016;14(1):10. DOI: 10.1186/s12953-016-0099-4

[70] Serafín-Higuera I., Garibay-Cerdenares O.L., Illades-Aguiar B. et al. Differential proteins among normal cervix cells and cervical cancer cells with HPV-16 infection, through mass spectrometry-based Proteomics (2D-DIGE) in women from Southern México // Proteome Sci. 2016. Vol. 14. No. 1. P. 10. DOI: 10.1186/s12953-016-0099-4

[71] Jin Y, Kim SC, Kim HJ, et al. Use of protein-based biomarkers of exfoliated cervical cells for primary screening of cervical cancer. Arch Pharm Res. 2018;41(4):438–449. DOI: 10.1007/s12272-018-1015-5

[72] Jin Y., Kim S.C., Kim H.J. et al. Use of protein-based biomarkers of exfoliated cervical cells for primary screening of cervical cancer // Arch. Pharm. Res. 2018. Vol. 41. No. 4. P. 438–449. DOI: 10.1007/s12272-018-1015-5

[73] Güzel C, Govorukhina NI, Wisman GBA, et al. Proteomic alterations in early stage cervical cancer. Oncotarget. 2018;9(26):18128–18147. DOI: 10.18632/oncotarget.24773

[74] Güzel C., Govorukhina N.I., Wisman G.B.A. et al. Proteomic alterations in early stage cervical cancer // Oncotarget. 2018. Vol. 9. No. 26. P. 18128–18147. DOI: 10.18632/oncotarget.24773

[75] Hwang YJ, Lee SP, Kim SY, et al. Expression of heat shock protein 60 kDa is upregulated in cervical cancer. Yonsei Med J. 2009;50(3):399–406. DOI: 10.3349/ymj.2009.50.3.399

[76] Hwang Y.J., Lee S.P., Kim S.Y. et al. Expression of heat shock protein 60 kDa is upregulated in cervical cancer // Yonsei Med. J. 2009. Vol. 50. No. 3. P. 399–406. DOI: 10.3349/ymj.2009.50.3.399

[77] Choi CH, Chung JY, Kang JH, et al. Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer. Gynecol Oncol. 2020;157(2):437–443. DOI: 10.1016/j.ygyno.2020.02.017

[78] Choi C.H., Chung J.Y., Kang J.H. et al. Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer // Gynecol. Oncol. 2020. Vol. 157. No. 2. P. 437–443. DOI: 10.1016/j.ygyno.2020.02.017

[79] Martínez-Rodríguez F, Limones-González JE, Mendoza-Almanza B, et al. Understanding cervical cancer through proteomics. Cells. 2021;10(8):1854. DOI: 10.3390/cells10081854

[80] Martínez-Rodríguez F., Limones-González J.E., Mendoza-Almanza B. et al. Understanding cervical cancer through proteomics // Cells. 2021. Vol. 10. No. 8. P. 1854. DOI: 10.3390/cells10081854

[81] Boichenko AP, Govorukhina N, Klip HG, et al. A panel of regulated proteins in serum from patients with cervical intraepithelial neoplasia and cervical cancer. J Proteome Res. 2014;13(11):4995–5007. DOI: 10.1021/pr500601w

[82] Boichenko A.P., Govorukhina N., Klip H.G. et al. A panel of regulated proteins in serum from patients with cervical intraepithelial neoplasia and cervical cancer // J. Proteome. Res. 2014. Vol. 13. No. 11. P. 4995–5007. DOI: 10.1021/pr500601w

[83] Guo X, Hao Y, Kamilijiang M, et al. Potential predictive plasma biomarkers for cervical cancer by 2D-DIGE proteomics and Ingenuity Pathway Analysis. Tumour Biol. 2015;36(3):1711–1720. DOI: 10.1007/s13277-014-2772-5

[84] Guo X., Hao Y., Kamilijiang M. et al. Potential predictive plasma biomarkers for cervical cancer by 2D-DIGE proteomics and Ingenuity Pathway Analysis // Tumour Biol. 2015. Vol. 36. No. 3. P. 1711–1720. DOI: 10.1007/s13277-014-2772-5

RIGHTS & PERMISSIONS

Eсо-Vector